MERTK and neoplasm: While it is difficult to fully disaggregate the effects of Mer inhibition in immune cells from those taking place concurrently in tumor cells, reviewed elsewhere (99), Mer remains a promising therapeutic target for anti-cancer therapy alone, or in combination with other immunotherapies.